In conclusion, DPP-4 has a neutral effect on weight or a minor reduction in weight, acarbose has mild effects, metformin and SGLT-2 inhibitors have moderate effects on weight loss, and some of the GLP-1 agonist drugs have the strongest and most promising results as anti-obesity drugs. This evidence concerns the gene SLC5A2 and obesity disorder.